Inhibrx Stock Jumps on Positive Cancer Trial Results

Key Highlights of the Study

Inhibrx Biosciences, stock symbol INBX, saw its shares climb 11.7% in premarket trading after releasing positive interim results from its Phase 2 HexAgon clinical trial. The study focused on the company's experimental cancer treatment, INBRX-106.

Trial Overview and Efficacy

The trial evaluated INBRX-106, an OX40 agonist, in combination with pembrolizumab for patients with head and neck cancer. The combination therapy achieved a confirmed Objective Response Rate of 44.0%. This figure significantly outperformed the 21.4% response rate observed in patients who received only pembrolizumab, marking a 22.6% absolute increase in efficacy. Three patients in the combination arm achieved a complete response, whereas none did in the control group.

Safety Profile and Future Outlook

The company reported that the combination treatment has a manageable safety profile consistent with similar immunotherapies. The most common adverse events were low-grade, and no treatment-related deaths occurred. Inhibrx plans to begin the Phase 3 portion of the study in the third quarter of 2026 and expects to release progression-free survival data in the fourth quarter of 2026.

Conclusion

The strong Phase 2 data provides a clear path forward for Inhibrx's oncology program. The positive clinical results and manageable safety have bolstered investor confidence, reflected in the stock's significant premarket gain.

FAQ

Q: What was the key result from the Inhibrx Phase 2 trial?
A: The combination of INBRX-106 and pembrolizumab showed a 44.0% objective response rate, compared to 21.4% for pembrolizumab alone.

Q: How did the market react to the news?
A: Inhibrx (INBX) shares jumped 11.7% in premarket trading following the data release.

Source: Investing.com